Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: Early experiences and challenges

European Respiratory Journal

Volumn 48, Issue 3, 2016, Pages 938-943

  Tadolini, Marina ^a   Garcia Prats, Anthony J ^b   D'Ambrosio, Lia ^c,d   Hewison, Catherine ^e   Centis, Rosella ^c   Schaaf, H Simon ^b   Marais, Ben J ^f   Ferreira, Hannetjie ^g   Caminero, Jose A ^h,i   Jonckheere, Sylvie ^e   Sinha, Animesh ^e   Herboczek, Krzysztof ^e   Khaidarkhanova, Zarema ^j   Hayrapetyan, Armen ^k   Khachatryan, Naira ^e   Urtkmelidze, Ia ^l   Loreti, Carolina ^e   Esposito, Susanna ^m   Matteelli, Alberto ⁿ   Furin, Jennifer ^o   Varaine, Francis ^e   Migliori, Giovanni Battista ^c   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c IRCCS   (Italy)

^d Public Health Consulting Group SAGL   (Switzerland)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Klerksdorp Tshepong Hospital   (South Africa)

^h INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

ⁱ HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^j Republican TB Dispensary   (Russian Federation)

^k Armenian National Tuberculosis Control Centre   (Armenia)

^l National Centre for Tuberculosis and Lung Disease   (Georgia)

^m UNIVERSITY OF MILAN   (Italy)

ⁿ UNIVERSITY OF BRESCIA   (Italy)

^o HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; TUBERCULOSTATIC AGENT;

AGE DISTRIBUTION; COMPASSIONATE USE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; CHILD; FEMALE; MALE;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; COMPASSIONATE USE TRIALS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 84986182673     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00705-2016     Document Type: Letter

References (16)

1. Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 2014; 383: 1572-1579.
2. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
3. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
4. Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186: 953-964.
5. World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd Edn. WHO/HTM/TB/2014.03. Geneva, World Health Organization, 2014. http://apps.who.int/medicinedocs/documents/s21535en/s21535en.pdf
6. Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016; 20: 177-186.
7. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402.
8. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
9. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
10. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
11. Lessem E, Cox H, Daniels C, et al. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. Int J Infect Dis 2015; 32: 56-60.
12. World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. WHO/HTM/TB/2014.11. Geneva, World Health Organization, 2014. http://apps. who.int/iris/bitstream/10665/130918/1/9789241548809-eng.pdf
13. Lachâtre M, Rioux C, Dû DL, et al. Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis 2016; 16: 294.
14. Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016; in press [DOI: 10.1183/13993003.00637-2016].
15. Matteelli A, D'Ambrosio L, Centis R, et al. Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis 2015; 15: 1131-1132.
16. Nachman S, Ahmed A, Amanullah F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis 2015; 15: 711-720.